Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically Ill patients undergoing CRRT

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 8, 2016, Pages 1377-1383

  Shotwell, Matthew S ^a   Nesbitt, Ross ^a   Madonia, Phillip N ^a   Gould, Edward R ^a   Connor, Michael J ^b   Salem, Charbel ^c   Aduroja, Olufemi A ^d   Amde, Milen ^e   Groszek, Joseph J ^a   Wei, Peilin ^a   Taylor, Maria E ^f   Tolwani, Ashita J ^f   Fissell, William H ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c King's Daughters Medical Center   (United States)

^d Marion General Hospital   (United States)

^e Veterans Affairs Southern Nevada Healthcare System   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Acute Kidney Injury; Anti Bacterial Agents; Critical Illness; Dialysis Solutions; extended infusion; Humans; Microbial Sensitivity Tests; pharmacokinetics; piperacillin; Renal Replacement Therapy

Indexed keywords

PIPERACILLIN; TAZOBACTAM; ANTIINFECTIVE AGENT; DIALYSIS FLUID; PENICILLANIC ACID; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; EFFLUENT; FEMALE; HEMODIALYSIS MACHINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MATHEMATICAL MODEL; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MORTALITY; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; ACUTE KIDNEY FAILURE; ANALOGS AND DERIVATIVES; BACTERIAL INFECTION; BLOOD; CHEMISTRY; COMPARATIVE STUDY; COMPLICATION; CRITICAL ILLNESS; HEMODIAFILTRATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; TIME FACTOR;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; DIALYSIS SOLUTIONS; FEMALE; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; TIME FACTORS;

EID: 85018322872     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.10260915     Document Type: Article

References (30)

1. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16: 3365-3370, 2005
2. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 294: 813-818, 2005
3. Uchino S, Bellomo R, Kellum JA, Morimatsu H, Morgera S, Schetz MR, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-Van Straaten HM, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators Writing Committee: Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int J Artif Organs 30: 281-292, 2007
4. Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu CY: Temporal changes in incidence of dialysis-requiring AKI. J AmSoc Nephrol 24: 37-42, 2013
5. Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P; VA/NIH Acute Renal Failure Trial Network: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359: 7-20, 2008
6. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S; RENAL Replacement Therapy Study Investigators: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361: 1627-1638, 2009
7. Woodrow G, Turney JH: Cause of death in acute renal failure. Nephrol Dial Transplant 7: 230-234, 1992
8. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jiménez R, Barroso S, Ortiz-Leyba C: Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 10: R111, 2006
9. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31: 2742-2751, 2003
10. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabó-Pallás T, Cayuela-Dominguez A, Marquez-Vacaro JA, Carbajal-Guerrero J, Garcia-Garmendia JL: Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: Amatched cohort study. J Antimicrob Chemother 61: 436-441, 2008
11. Bauer SR, Salem C, Connor MJ Jr., Groszek J, Taylor ME, Wei P, Tolwani AJ, Fissell WH: Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol 7: 452-457, 2012
12. Afshartous D, Bauer SR, Connor MJ, Aduroja OA, Amde M, Salem C, Groszek JJ, Fissell WH: Pharmacokinetics and pharmacodynamics of imipenem and meropenem in critically ill patients treatedwith continuous venovenous hemodialysis. Am J Kidney Dis 63: 170-171, 2014
13. Shotwell MS, Madonia PN, Connor MJ, Amde M, Salem C, Aduroja OA, Bauer SR, Groszek JJ, Fissell WH: Ciprofloxacin pharmacokinetics in critically ill patients receiving concomitant continuous venovenous hemodialysis. Am J Kidney Dis 66: 173-175, 2015
14. Connor MJ Jr., Salem C, Bauer SR, Hofmann CL, Groszek J, Butler R, Rehm SJ, Fissell WH: Therapeutic drug monitoring of piperacillin-tazobactamusing spent dialysate effluent in patients receiving continuous venovenous hemodialysis. Antimicrob Agents Chemother 55: 557-560, 2011
15. Matzke GR, Aronoff GR, Atkinson AJ Jr., Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P: Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 1122-1137, 2011
16. Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL; Kidney Health Initiative: Pharmacokinetic assessment in patients receiving continuous RRT: Perspectives from the Kidney Health Initiative. Clin J AmSoc Nephrol 10: 159-164, 2015
17. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, FazeliMR: Clinical efficacy of continuous infusion of piperacillin comparedwith intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 28: 122-127, 2006
18. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F: Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 51: 3304-3310, 2007
19. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 37: 926-933, 2009
20. Roberts JA, Lipman J: Tissue distribution of beta-lactam antibiotics: Continuous versus bolus dosing. J Pharm Pract Res 39: 219-222, 2009
21. Drusano GL: Antimicrobial pharmacodynamics: Critical interactions of ‘bug and drug’. Nat Rev Microbiol 2: 289-300, 2004
22. Clinical and Laboratory Standards Institute: Clinical Laboratory Standards I. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement, Wayne, PA, Clinical and Laboratory Standards Institute, 2011
23. European Committee on Antimicrobial Susceptibility T: Breakpoint Tables for Interpretation of MICs and Zone Diameters, European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Basel, Switzerland, European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2012
24. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG: Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57: 2809-2814, 2013
25. R Core Team: R: A Language and Environment for Statistical Computing, Vienna, Austria, R Foundation for Statistical Computing, 2013
26. Pinheiro J, Bates D, DebRoy S, Sarkar D; R Core Team: nlme: Linear and Nonlinear Mixed Effects Models. R Package Version 3.1-109, 2013
27. Pinheiro J, Bates D, DebRoy S, Sarkar D; TeamRDC: nlme: Linear and Nonlinear Mixed Effects Models, 2012
28. Jamal JA, Roberts DM, Udy AA, Mat-Nor MB, Mohamad-Nor FS, Wallis SC, Lipman J, Roberts JA: Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 46: 39-44, 2015
29. Dalla Costa T, Nolting A, Kovar A, Derendorf H: Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. J Antimicrob Chemother 42: 769-778, 1998
30. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases: Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions. Lancet Infect Dis 14: 498-509, 2014